bih.button.backtotop.text
BROWSE BY TEST NAME
#
%
1
2
3
5
8
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Z
Clear
 
Test Code (รหัสการทดสอบ):
092-10-0084

Order Name (ชื่อการทดสอบ):
APOE Alzheimer report (WES add-on panel)

 
Specimen / Container (สิ่งส่งตรวจ/ภาชนะ):
Specimen: Not required

Document required: Consent for Genomic Medicine Testing
 
Turnaround Time (ระยะเวลารอผล):
Report within 2 weeks
 
Useful For (ประโยชน์การทดสอบ):
Healthy people who are interested to know about the risk of APOE gene for developing Alzheimer's Disease.
 
Methodology (วิธีการทดสอบ):
Data analysis using Whole Exome Sequencing (WES) data
 
Test List In Profile (การทดสอบใน Profile):
APOE Alzheimer report
 
AliasesName (ชื่อเรียกอื่นๆ) :
whole exome sequencing, WES, APOE, Alzheimer
 
 
 
Test Code (รหัสการทดสอบ):
092-10-0084

Order Name (ชื่อการทดสอบ):
APOE Alzheimer report (WES add-on panel)

 
Patient Preparation (การเตรียมตัวผู้ป่วย):
Patient must has Whole exome sequencing (WES) before order this test
 
Collection Specimen Or Container (สิ่งส่งตรวจ/ภาชนะ):
Specimen: Not required

Document required: Consent for Genomic Medicine Testing
 
Specimen Testing Type (สิ่งส่งตรวจที่ใช้ในการทดสอบ):
Not required
 
Sub Mission Container (ภาชนะส่งตรวจ):
N/A
 
 
 
Test Code (รหัสการทดสอบ):
092-10-0084

Order Name (ชื่อการทดสอบ):
APOE Alzheimer report (WES add-on panel)

 
Turnaround Time (ระยะเวลารอผล):
Report within 2 weeks
 
Performing Location (หน่วยงานที่ทำการทดสอบ):
Research and Development laboratory, Tel 14152
 
 
 
Test Code (รหัสการทดสอบ):
092-10-0084

Order Name (ชื่อการทดสอบ):
APOE Alzheimer report (WES add-on panel)

 
 
Clinical Information (ข้อมูลทางคลินิก):
Apolipoprotein E (ApoE) locates on 19q13.2 and consists of 299 amino in length. It plays an important role in cholesterol transportation and metabolism. Three most common alleles of ApoE are e3 (Cys112/Arg158), e2(Cys112/Cys158) and e4(Arg112/Arg158). Among these three alleles, e3 is the wildtype and most commonly found. Mutation in ApoE might increase or decrease the risk for Alzheimer’s disease. Individuals with APOE e3/e4 genotype have a three-to-four-fold relative risk while individuals with APOE e4/e4 genotype have a 15-fold relative risk compared to those with the APOE e3/e3 genotype. Other than the risk at Late-onset Alzheimer developing, these mutations are related with the age of onset for the disease. The average age of developing Late-onset Alzheimer is 68 years at 94% for HomozygyousE4, 76 years at 47% frequency for hetrozygousE4 and 84 years at 20% frequency for those who do not carry E4.
 
Clinical Reference (เอกสารอ้างอิง):
1. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol. 2002 Mar 15;155(6):487-95. 
2. Schaefer EJ, Lamon-Fava S, Johnson S, Ordovas JM, Schaefer MM, Castelli WP, Wilson PW. Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels. Results from the Framingham Offspring Study. Arterioscler Thromb. 1994 Jul;14(7):1105-13. 
3. Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med. 2004 Jul 20;141(2):137-47. 
4. Goldman JS, Hahn SE, Catania JW, LaRusse-Eckert S, Butson MB, Rumbaugh M, Strecker MN, Roberts JS, Burke W, Mayeux R, Bird T; American College of Medical Genetics and the National Society of Genetic Counselors. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med. 2011 Jun;13(6):597-605. 
5. Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med. 2016 May;18(5):421-30. 
6. Li Z, Shue F, Zhao N, Shinohara M, Bu G. APOE2: protective mechanism and therapeutic implications for Alzheimer's disease. Mol Neurodegener. 2020 Nov 4;15(1):63.